ArticleEye (London, England)2026
Towards an objective classification of pachychoroid disease and its risk of progression.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo identify clinical phenotypes in pachychoroid disease (PD), characterise long-term progression patterns, and evaluate the effect of photodynamic therapy (PDT) using machine learning and longitudinal probabilistic modelling.
methodsThis retrospective cohort study included 973 eyes from 663 patients (mean age 54.4 ± 12.8 years; 80% male) diagnosed with PD. Eyes were classified based on macular fluid status into no history, primary, recurrent, or resolved fluid categories. Multimodal imaging data were analysed at baseline and at the final follow-up visit ( > 5 years). Phenotypic clusters were identified using cross-validated K-means clustering on imaging and clinical features. Longitudinal changes in phenotype were evaluated with Markov modelling, including the effect of photodynamic therapy (PDT) on cluster transitions. Visual acuity (VA) changes were estimated with linear mixed models.
resultsFour distinct clusters were defined: Cluster 1 (233 eyes) consisted of younger patients exhibiting active fluid and mild structural alterations (LogMAR 0.16); Cluster 2 (317 eyes) represented mild or resolving PD with optimal VA (LogMAR 0.05); Cluster 3 (336 eyes) featured chronic fluid accumulation, significant structural damage, and moderate visual impairment (LogMAR 0.35); Cluster 4 (87 eyes) corresponded to severe bilateral disease and worst VA (LogMAR 0.66). At baseline, Clusters 1 to 4 were distributed as follows: 22.7%, 25.5%, 39.8%, and 12.0%. Over follow-up (mean 90.2 ± 24 months), the distribution shifted to 3.7%, 32.4%, 36.6%, and 27.3%, indicating progression toward more advanced phenotypes. Cluster 1 had frequent transitions, with 53% eyes progressing to Cluster 2 and 37% to Cluster 3. Cluster 4 showed minimal transition (96% stable). Interaction indicated greater visual deterioration in more severe baseline phenotypes (p = 0.01). PDT administration did not significantly alter disease progression (p > 0.5).
conclusionPD exhibits distinct, dynamically evolving phenotypes with measurable probabilistic progression over time. As this represents an exploratory, data-driven analysis, the identified clusters should be interpreted as hypothesis-generating. Significant structural changes occurred despite PDT, underscoring the need for therapies capable of modifying the underlying disease course rather than its local manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.